Microdosed Atropine 0.1% and 0.01% Ophthalmic Solutions for Reduction of Pediatric Myopia Progression
Status:
Recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
This study evaluates the progression of myopia in participants using microdosed atropine
0.01%, atropine 0.1%, or placebo ophthalmic solution. Eligible subjects will administer study
medication daily in each eye for 48 months. Efficacy and safety assessments will be performed
at visits scheduled for 1, 6, 12, 18, 24, 30 and 36 months after initiation of medication
use. Subjects will be re-randomized at the 36 month visit, then followed at 6 month intervals
for an additional year.